Oral hypoglycemic agents in pregnancy: Their time has come

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 12, Issue 6, 2002, Pages 376-383

  Langer, O ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Hypoglycemic agents; Pregnancy; Type 2 diabetes

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; MEGLITINIDE; METFORMIN; NICOTINAMIDE; PHENFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE;

BLOOD PLACENTA BARRIER; CLINICAL TRIAL; CONFERENCE PAPER; DECISION MAKING; DIET; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FETUS MALFORMATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLACENTAL TRANSFER; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036945730     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/jmf.12.6.376.383     Document Type: Conference Paper

References (64)

1. Langer O. Oral hypoglycemic agents and the pregnant diabetic: 'From bench to bedside'. Semin Perinatol 2002;26:215-24
2. Freinkel N, Metzger BE, Phelps RL, et al. Gestational diabetes mellitus: heterogeneity of maternal age, weight, insulin secretion, HLA antigens, and islet cell antibodies and the impact of maternal metabolism on pancreatic B-cell function and somatic growth in the offspring. Diabetes 1995;34 (Suppl 2):1-7
3. Catalano PM, Virgo KM, Bernstein IM, et al. Incidence and risk factors associated with abnormal glucose tolerance in women with gestational diabetes. Am J Obstet Gynecol 1991;165:914-19
4. Catalano PM, Tyzbir ED, Wolfe RR, et al. Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. Am J Physiol 1993;264:E60-7
5. Langer N, Langer O. Emotional adjustment to diagnosis and intensified treatment of gestational diabetes. Obstet Gynecol 1994;84:329-34
6. Langer O, Langer N, Piper JM, et al. Is cultural diversity a factor in self-monitoring blood glucose in gestational diabetes? J Assoc Acad Minor Phys 1995;6:73-7
7. Spirito A, Williams C, Ruggiero L, et al. Psychological impact of the diagnosis of gestational diabetes. Obstet Gynecol 1989;73:562-6
8. Langer O. The use of oral hypoglycemic agents in the pregnant diabetic woman. Isr J Obstet Gynecol 2001;12:179-84
9. Langer O. When diet fails: insulin and oral hypoglycemic agents as alternatives for the management of gestational diabetes. J Maternal-Fetal Med 2002;11:1-8
10. Langer O. Insulin and other treatment alternatives in gestational diabetes mellitus. Prenat Neonat Med 1998;3:542-9
11. Turner RC, Cull CA, Fright V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. J Am Med Assoc 1999;281:2005-12
12. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Ref 1999;7:139-53
13. Douglas CP, Richards R. Use of chlorpropamide in the treatment of diabetes in pregnancy. Diabetes 1967;16:60-1
14. Jackson WPU, Campbell GD, Notelovitz M, Blumson D. Tolbutamide and chloropropamide during pregnancy in human diabetics. Diabetes 1963;(Suppl):98-101
15. Sutherland HW, Bewsher PD, Cormack JD, et al. Effect of moderate dosage of chloropropamide in pregnancy on fetal outcome. Arch Dis Child 1974;49:283-91
16. Stowers JM, Sutherland HW. The use of sulphonylureas bigunides and insulin in pregnancy. In Stowers JM, Sutherland HW, eds. Carbohydrate Metabolism in Pregnancy and the Newborn. Edinburgh: Churchill Livingstone, 1975:205-20
17. Coetzee EJ, Jackson WPU. Oral hypoglycemics in the first trimester and fetal outcome. S Afr Med J 1984;65:635-7
18. Coetzee EJ, Jackson WPU. Pregnancy in established non-insulin-dependent diabetics. S Afr Med J 1980;61:795-802
19. Notelowitz M. Oral hypoglycemic therapy in diabetic pregnancies. Lancet 1974;2:902-3
20. Malins JM, Cooke AM, Pyke DA, et al. Sulfonylurea drugs in pregnancy [Letter]. Br Med J 1964;2:187
21. Notelowitz M. Sulfonylurea therapy in the treatment of the pregnant diabetic. S Afr Med J 1971;45:226-9
22. Coetzee EJ, Jackson WPU. The management of noninsulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract 1986;1:281-7
23. Coetzee EJ, Jackson WPU. Diabetes newly diagnosed in pregnancy: a 4-year study at Groote Schuur Hospital. SA Med Tydskrif 1979:467-75
24. Coetzee EJ, Jackson WPU. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979;16:241-5
25. Kemball ML, McIvert C, Milner RDG, et al. Neonatal hypoglycemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child 1970;45:696-701
26. Zucker P, Simon G. Prolonged symptomatic neonatal hypoglycemia associated with maternal chlorpropamide therapy. Pediatrics 1968;42:824-5
27. Piacquadio K, Hollingsworth DR, Murphy H. Effects of in-utero exposure to oral hypoglycemic drugs. Lancet 1991;338:866-9
28. Audus KL. Controlling drug delivery across the placenta. Eur J Pharm Sci 1999;8:161-5
29. Dancis J. Placental physiology. In Kretchmer N, Quilligan EJ, Johnson JD, eds. Prenatal and Perinatal Biology and Medicine, Physiology and Growth. Vol 1. Chur, Switzerland: Harwood Academic Publishers, 1987:1-33
30. Enders AC, Blakenship TN. Comparative placental structure. Adv Drug Del Rev 1999;38:3-16
31. Ala-Kokko TL, Vahakangas K, Pelkonen O. Placental function and principles of drug transfer. Acta Anaesthesiol Scand 1993;37:47-9
32. Sibley CP. Review article: mechanism of ion transfer by the rat placenta: a model for the human placenta? Placenta 1994;15:675-91
33. Smithberg M, Runner MN. Teratogenic effects of hypoglycemic treatments in inbred strains of mice. Am J Anat 1963;113:479-89
34. Sivan E, Feldman B, Dolitzki M, et al. Glyburide crosses the placenta in vivo in pregnant rats. Diabetologia 1995;38:753-6
35. Smoak IW. Teratogenic effects of chlorpropamide in mouse embroyos in vitro. Teratology 1992;45:474
36. Smoak IW, Sadler TW. Embryopathic effects of short-term exposure to hypoglycemia in the mouse. Am J Obstet Gynecol 1990;163:619-24
37. Denno KM, Sadler TW. Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology 1994;49:260-6
38. Shepard TH. Catalog of Teratogenic Agents, 8th edn. Baltimore: Johns Hopkins University Press, 1995:270
39. Schardein JL. Chemically Induced Birth Defects, 2nd edn. New York: Marcel Dekker, 1993:417-18
40. Towner D, Kjos SL, Montoro MM, et al. Congenital malformations in pregnancies complicated by NIDDM. Diabetes Care 1995;18:1446-51
41. Langer O, Conway D, Berkus M, et al. There is no association between hypoglycemic use and fetal anomalies. Am J Obstet Gynecol 1999;180:S38(abstr)
42. Koren G. NIH/FDA Toxicology in Pregnancy Conference, Toronto, December 2000
43. Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002;77:520-5
44. Jakubwicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002:87:524-9
45. Langer O, Conway DL, Berkus MD, et al. A comparison of glyburide vs. insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343:1134-8
46. Rossetti L, Giaaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13:610-30
47. Simonson DC, Farrannini E, Bevilacqua S, et al. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes Care 1984;33:838-45
48. Groop L, Luzi L, Melanger A, et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987;36:1320-8
49. Groop LC, Barzilai N, Ratheiser K, et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 1991;14:724-7
50. DeFronzo RA, Simonson DC. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care 1984;7:72-80
51. Hardmons J, ed. Goodman and Gillman's The Pharmacologic Basis of Therapeutics, 9th edn. New York: McGraw Hill, 1996:1712-92
52. Bristol-Myers Squibb. Product information. Glucophage. 1997
53. Klepser TB, Kelly MW. Metformin hydrochloride: an anti-hyperglycemic agent. Am J Health-Syst Pharm 1997;54:893-903
54. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:550-4
55. Elliot B, Langer O, Schenker S, Jonhson RF. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 1991;165:807-12
56. Koren G. Glyburide and fetal safety; transplacental pharmacokinetic considerations. Reprod Toxicol 2001;15:225-9
57. Brandes JM, Travoloni N, Potter JB, et al. A new recycling technique for human placental cotyledon perfusion: application to studies of the fetomaternal transfer of glucose, insulin, and antipyrine. Am J Obstet Gynecol 1983;146:800-6
58. Schenker S, Johnson R, Hays S, et al. Effects of nicotine and nicotine/ethanol on human placental amino acid transfer. Alcohol 1989;6:289-96
59. Schenker S, Dicke J, Johnson R, et al. Human placental transport of cimetidine. J Clin Invest 1987;80:1428-34
60. Elliot B, Schenker S, Langer O, et al. Comparative placental transport of oral hypoglycemic agents. A model of human placental drug transfer. Am J Obstet Gynecol 1994;171:653-60
61. Elliot B, Langer O, Schussling F. A model of human placental drug transfer. Am J Obstet Gynecol 1997;176:527-30
62. Chmait R, Dinise T, Daneshmand S, et al. Prospective cohort study to establish predictors of glyburide success in gestational diabetes mellitus. Am J Obstet Gynecol 2001;185:(abstr)
63. Kitzmiller J. Limited efficacy of glyburide for glycemic control. Am J Obstet Gynecol 2001;185:(abstr)
64. Harris MI, et al. Diabetes Care 1999;22:403-8